Xeris presents endocrine data for Xeris Biopharma stock

Published on 10/20/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xeris outlines data from 3 endocrine meetings on October 15, 2026. Xeris Biopharma stock trades at EUR 9.86 at Lang & Schwarz on October 20, 2026.

Clinical pipeline and reporting calendar

Xeris announced presentations at 3 scientific meetings on October 15, 2026.
Barclays raised its target from USD 12.00 to USD 14.00 on October 6, 2026.
Xeris Biopharma stock traded at EUR 9.86 at 1:43 p.m. CEST at Lang & Schwarz on October 20, 2026.
Third-quarter results are scheduled for November 5, 2026.

XERS, US98422E1038, Illustration mit AI erstellt.

Xeris Biopharma Holdings (ISIN US98422E1038) was trading at EUR 9.86 at Lang & Schwarz on October 20, 2026 at 1:43 p.m. CEST. On October 15, 2026, Xeris Biopharma announced clinical and scientific presentations covering Gvoke, Recorlev and the investigational XP-8121 program.

Three meetings, three dated updates

The company linked the data to 3 scientific meetings. The Breakthrough T1D Clinical and Research Congress ran from October 9 to October 10, 2026, and featured real-world research on ready-to-use glucagon prescribing. The Cardiometabolic Health Congress took place from October 15 to October 16, 2026, with a Recorlev case study involving cortisol normalization and cardiometabolic measures.

The American Thyroid Association meeting is scheduled for November 4 to November 7, 2026. Xeris plans to present a TriNetX analysis of levothyroxine treatment records and thyroid-stimulating hormone data on November 6, 2026, according to the October 15 release.

What does the target reset mean?

Barclays maintained an Overweight rating and raised its Xeris target from USD 12.00 to USD 14.00 in a research note dated October 6, 2026, Benzinga reported. The higher target puts the analyst view above the latest Nasdaq reference price of USD 10.95 dated October 19, 2026, although the currencies are different and are not combined here.

Three events shape the recent timeline

On October 6, 2026, Barclays lifted its target from USD 12.00 to USD 14.00. On October 13, 2026, Xeris filed 2 patent infringement lawsuits tied to its KEVEYIS product and U.S. Patent No. 12,758,502, as stated in an SEC filing. On October 15, 2026, the company announced data presentations at 3 meetings.

The next two dated milestones are the American Thyroid Association presentation on November 6, 2026, and the expected third-quarter earnings announcement on November 5, 2026. MarketBeat lists the report before the market opens, with a conference call at 8:30 a.m. ET.

Price and upcoming evidence

The clinical presentations add evidence around Xeris's commercial portfolio and pipeline, while the November dates give investors two measurable catalysts. Xeris's portfolio includes Gvoke for severe hypoglycemia, Recorlev for endogenous hypercortisolemia and Keveyis for primary periodic paralysis, according to the October 15 company release.

Xeris Biopharma Holdings was trading at EUR 9.86 at Lang & Schwarz on October 20, 2026 at 1:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Xeris Biopharma stock.